Abstract
Sulbactam (SBT), a new β-lactamase inhibitor, in combination with cefoperazone (CPZ) was studied for the clinical evaluation in the field of obstetrics and gynecology.
SBT/CPZ was given to 6 cases with the following infections; 4 of pyometra, 1 of Doumws-abscess and 1 of pelvic cellulitis. Five cases were old patients accompanied by cancers, and 2 cases were refractory to other antibiotics therapy.
The clinical efficacy was excellent in 1 case, good in 3 cases, poor in 2 cases.
No side effects nor abnormal laboratory findings associate with the agent were observed.
